← ANALYST RATINGS · TIPRANKS
Rani Therapeutics Holdings (RANI): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $6.75, the highest $11.00, the lowest $5.00. The average is +954.7% from the last price of $0.64.
Analyst ratings 5
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.70 → $0.64−8.2% | Hold | 0.0% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.68 → $0.63−7.8% | Hold | −2.0% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.67 → $0.63−4.9% | Hold | −0.9% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.65 → $0.61−5.6% | Hold | −4.5% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.68 → $0.63−7.8% | Hold | −2.0% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.65 → $0.61−5.1% | Hold | −4.1% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.78 → $0.70−10.6% | Hold | +8.9% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.76 → $0.68−10.6% | Hold | +6.2% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.75 → $0.67−10.6% | Hold | +4.2% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.72 → $0.65−10.6% | Hold | +1.1% | Upgrade | 15.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.76 → $0.68−10.6% | Hold | +6.2% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.72 → $0.65−10.6% | Hold | +1.1% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.83 → $0.78−6.1% | Hold | +21.9% | Reiterated | 13.10.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.81 → $0.76−6.2% | Hold | +18.9% | Reiterated | 13.10.26on TipRanks 07:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.80 → $0.75−6.2% | Hold | +16.6% | Reiterated | 13.10.26on TipRanks 07:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.77 → $0.72−6.1% | Hold | +13.1% | Upgrade | 13.10.26on TipRanks 07:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.81 → $0.76−6.2% | Hold | +18.9% | Reiterated | 13.10.26on TipRanks 07:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.77 → $0.72−6.1% | Hold | +13.1% | Reiterated | 13.10.26on TipRanks 07:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.82 → $0.83+0.8% | Hold | +29.8% | Reiterated | 11.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.80 → $0.81+0.9% | Hold | +26.7% | Reiterated | 11.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.79 → $0.80+0.9% | Hold | +24.2% | Reiterated | 11.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.76 → $0.77+0.9% | Hold | +20.5% | Upgrade | 11.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.80 → $0.81+0.9% | Hold | +26.7% | Reiterated | 11.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.76 → $0.77+0.9% | Hold | +20.5% | Reiterated | 11.10.26on TipRanks 05:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.84 → $0.82−2.1% | Hold | +28.7% | Reiterated | 09.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.82 → $0.80−2.2% | Hold | +25.6% | Reiterated | 09.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.81 → $0.79−2.2% | Hold | +23.1% | Reiterated | 09.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.78 → $0.76−2.3% | Hold | +19.4% | Upgrade | 09.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.82 → $0.80−2.2% | Hold | +25.6% | Reiterated | 09.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.78 → $0.76−2.3% | Hold | +19.4% | Reiterated | 09.10.26on TipRanks 05:05 | — | |
| Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% | H.C. Wainwright | $11.00 | Buy | +1,618.8% | Reiterated | 06.10.26on TipRanks 06:30 | +6.4%next day −1.7% · 5 days −11.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.84 | Hold | +31.6% | Reiterated | 05.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.82 | Hold | +28.4% | Reiterated | 05.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.81 | Hold | +25.9% | Reiterated | 05.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.78 | Hold | +22.2% | Upgrade | 05.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.82 | Hold | +28.4% | Reiterated | 05.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.78 | Hold | +22.2% | Reiterated | 05.10.26on TipRanks 05:05 | — | |
| Michael Okunewitch★★★★★★★★★★#11525 · hits 36% · avg −3.3% | Maxim Group | $5.00 | Buy | +681.2% | Reiterated | 20.08.26on TipRanks Aug 24 02:55 | −6.3%next day +3.0% · 5 days −0.8% | ↗ |
| Andreas Argyrides★★★★★★★★★★#1658 · hits 46% · avg +10.2% | Chardan Capital | $6.00 | Buy | +837.5% | Initiated | 18.08.26on TipRanks Aug 19 05:35 | +4.4%next day +10.8% · 5 days +8.2% | ↗ |
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $5.00 | Buy | +681.2% | Reiterated | 17.08.26on TipRanks Aug 13 08:40 | −1.3%next day +0.1% · 5 days +8.7% | ↗ |
| Daniel Brims★★★★★★★★★★#12312 · hits 19% · avg −36.9% | Lake Street | $9.00 | Buy | +1,306.2% | Reiterated | 18.05.26on TipRanks May 19 04:10 | −9.9%next day −8.4% · 5 days −4.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Rani Therapeutics Holdings
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 06.10.26: target $6.75 at a price of $0.77 (+772.1%); now: $6.75 at $0.64 (+954.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 6 | 11 | 11 | 11 | 6 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.05 (from $-0.05 to $-0.04). Last quarter: $-0.04.
Sales
Next quarter’s sales estimate — $1M (from $0M to $2M). Last quarter: $2M.
Best top-analyst consensus in the sector · Healthcare
About Rani Therapeutics Holdings
- CEO: Talat Imran
- Employees: 70
- 2051 Ringwood Avenue, San Jose, CA, 95131, US
- www.ranitherapeutics.com
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Data from the stock’s TipRanks forecast page, read 146 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗